Recent Conference Coverage
There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
At the 2016 ASCO meeting, Vice President Joe Biden spoke about his vision for comprehensive data-sharing as part of the Cancer MoonShot initiative.
Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.
Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
A nurse-facilitated oral chemotherapy care model has improved delivery times, patient satisfaction, and co-pay support at a Connecticut cancer hospital.
Follow-up telephone calls and clinician assessment may be an effective strategy to identify early which patients require support with adhering to oral cancer therapy.
A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.
Instituting a Chemotherapy Safety Committee and developing an administration process successfully standardized the inpatient oral chemotherapy administration process.
A formal nursing practice was developed to promote patient safety and adherence with oral chemotherapy.
Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.
A central venous catheter self-management education program is an effective nursing intervention to promote long-term self-management of a CVC for discharged patients with cancer.
The formation of a multidisplinary taskforce and the introduction of improved products successfully reduced the rates of catheter associated urinary tract infections (CAUTI) at an oncology hospital.
Daily chlorhexidine gluconate bathing on all patients with ports and tunneled catheters decreased the rates of CLABSI on an inpatient oncology unit.
Formation of a multidisciplinary team and a focus on evidence-based interventions successfully reduced the rate of central line bloodstream infections (CLABSI) on an inpatient oncology unit.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring
A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
Reasons for the continuing increase in cases of young-onset colorectal cancer, despite a decline in the overall rate of the disease in recent years, are unclear.
- PMPS: A Common Late Effect of Surgery and Radiation for Breast Cancer
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Physical Activity May Reduce Mortality by 44% in Patients With Breast Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
- Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer
- Nurses Are Key to Referrals to Inpatient Integrative Medicine Services
- Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma
- Poor Compliance to Adjuvant Chemo Linked to Poorer Survival in Rectal Cancer
- Users Support Indoor Tanning Device Age Restrictions, Stronger Health Warnings, But Not Total Ban
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|